enGene Holdings: Mid-2024 NMIBC Data Could Lead To EG-70 BLA Filing [Seeking Alpha]
enGene Holdings Inc. (ENGN)
Company Research
Source: Seeking Alpha
If positive results are achieved from the release of results from the phase 1/2 registrational LEGEND study, then a Biologics Licensing Application of EG-70 to the FDA could happen in 2025. The global non-muscle invasive bladder cancer market is expected to reach $5.5 billion by 2031. Potential to expand to the entire bladder cancer market and beyond eventually, because of the versatility of its non-viral DDX platform technology it has. Looking for a portfolio of ideas like this one? Members of Biotech Analysis Central get exclusive access to our subscriber-only portfolios. Learn More » enGene Holdings Inc. NASDAQ: ENGN ) is a biotech to keep an eye on with respect to the middle part of this year. That's because it is gearing up to report interim results from its open-label phase 1/2 LEGEND study, which is using EG-70 [detalimogene voraplasmid] for the treatment of patients with BCG-unresponsive non-muscle invasive bladder cancer [NMIBC]. Such results from this registrational
Show less
Read more
Impact Snapshot
Event Time:
ENGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ENGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ENGN alerts
High impacting enGene Holdings Inc. news events
Weekly update
A roundup of the hottest topics
ENGN
News
- enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
- enGene to Present Details of its Pivotal Phase 1/2 LEGEND Study of EG-70 in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in situ at the American Urology Association 2024 Annual MeetingPR Newswire
- enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $30.00 price target on the stock.MarketBeat
- enGene Holdings Inc. (NASDAQ: ENGN) is now covered by analysts at Guggenheim. They set a "buy" rating and a $34.00 price target on the stock.MarketBeat
- engender Announces Hiring of Dr. Raja Ruth as Senior Vice President, Urologic Oncology and Clinical DevelopmentPR Newswire
ENGN
Sec Filings
- 4/25/24 - Form 424B3
- 4/22/24 - Form 4
- 4/18/24 - Form ARS
- ENGN's page on the SEC website